Sensei Biotherapeutics Reports Full Year 2021 Financial Results and Business Highlights
- Reported preclinical proof of concept data from TMAb platform demonstrating potent and selective pH-dependent binding to “active” VISTA - - Initiated 2 new therapeutic programs... | March 10, 2022